Avalo Therapeutics, Inc. (AVTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 7M 14M 21M Q1 '20: 6.9M Q2 '20: 6.9M Q3 '20: 5.8M Q4 '20: 6.7M Q1 '21: 4.4M Q2 '21: 6.4M Q3 '21: 6.7M Q4 '21: 5.4M Q1 '22: 6.1M Q2 '22: 3.8M Q3 '22: 17.4M Q4 '22: 18.1M Q1 '23: 17.4M Q2 '23: 17M Q3 '23: 2.2M Q4 '23: 1.9M Q1 '24: 1.4M Q2 '24: 807K Q3 '24: 820K Q4 '24: 441K Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Gross Profit TTM

0 15M 30M 45M Q4 '17: 26.8M Q1 '18: 30.4M Q2 '18: 33.6M Q3 '18: 9.5M Q4 '19: 6.2M Q1 '20: 5.7M Q2 '20: 6.6M Q3 '20: 5.5M Q4 '20: 6.4M Q1 '21: 4.1M Q2 '21: 6.1M Q3 '21: 5.5M Q4 '21: 3.9M Q1 '22: 4M Q2 '22: 156K Q3 '22: 14.1M Q4 '22: 14.6M Q1 '23: 14.1M Q2 '23: 14.6M Q3 '23: 124K Q1 '18 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -80.5M Q4 '21: -82.1M Q1 '22: -72.4M Q2 '22: -67.1M Q3 '22: -46.5M Q4 '22: -37.4M Q1 '23: -25.4M Q2 '23: -20.7M Q3 '23: -28.5M Q4 '23: -27.4M Q1 '24: -51.3M Q2 '24: -53.8M Q3 '24: -62.9M Q4 '24: -68.5M Q1 '25: -50.4M Q2 '25: -60.2M Q3 '25: -66.5M Q4 '25: -72.9M Q1 '26: -79.2M Q2 '26: -91.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -80.8M Q4 '21: -84.4M Q1 '22: -75.7M Q2 '22: -71.6M Q3 '22: -51M Q4 '22: -41.7M Q1 '23: -29.6M Q2 '23: -24.8M Q3 '23: -33.2M Q4 '23: -31.5M Q1 '24: -142.9M Q2 '24: -36.2M Q3 '24: -8M Q4 '24: -35.1M Q1 '25: 73M Q2 '25: -46.2M Q3 '25: -99.9M Q4 '25: -78.3M Q1 '26: -84.7M Q2 '26: -100.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

-2.5M 0 2.5M 5M 7.5M Q4 '17: 635.6K Q1 '18: 1.5M Q2 '18: 2.9M Q3 '18: 6M Q4 '19: -566.5K Q1 '20: -1.3M Q2 '20: 321.6K Q3 '20: 266.2K Q4 '20: 300K Q1 '21: 311K Q2 '21: 316K Q3 '21: 1.1M Q4 '21: 1.5M Q1 '22: 2.1M Q2 '22: 3.6M Q3 '22: 3.2M Q4 '22: 3.4M Q1 '23: 3.3M Q2 '23: 2.4M Q3 '23: 2.1M Q1 '18 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -68.2M Q4 '21: -70.9M Q1 '22: -68.6M Q2 '22: -61.9M Q3 '22: -39.9M Q4 '22: -26.8M Q1 '23: -20.7M Q2 '23: -19.3M Q3 '23: -31.9M Q4 '23: -30.7M Q1 '24: -26.8M Q2 '24: -32.1M Q3 '24: -36.8M Q4 '24: -49.1M Q1 '25: -52.3M Q2 '25: -47.4M Q3 '25: -52.3M Q4 '25: -51.5M Q1 '26: -59.7M Q2 '26: -68.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q1 '18: 14.5M Q2 '18: 15.9M Q3 '18: -3.8M Q4 '18: -3.7M Q1 '19: -6.7M Q2 '19: -13.1M Q3 '19: -20.2M Q4 '19: -19.4M Q1 '20: -21.8M Q2 '20: -23.6M Q3 '20: -27.9M Q4 '20: -40.6M Q1 '21: -53.2M Q2 '21: -63.8M Q3 '21: -68.3M Q4 '21: -71M Q1 '22: -68.7M Q2 '22: -62.1M Q3 '22: -40M Q4 '22: -26.8M Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '16: 8.8M Q3 '17: 21.4M Q3 '18: 34.6M Q1 '22: 9.4M Q2 '22: 9.4M Q3 '22: 9.4M Q1 '23: 48.8K Q2 '23: 58.2K Q3 '23: 194.9K Q1 '24: 859.4K Q2 '24: 7.7M Q3 '24: 10.8M Q1 '25: 10.5M Q2 '25: 10.8M Q3 '25: 14M Q1 '26: 20.1M Q2 '26: 43.6M Q3 '17 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1500.00 -1000.00 -500.00 0.00 500.00 1000.00 1500.00 Q4 '16: -1.86 Q1 '17: -1.46 Q2 '17: -1.19 Q3 '17: 0.03 Q4 '17: 0.08 Q1 '18: 0.15 Q2 '18: 0.10 Q3 '18: -1.13 Q4 '18: -1.17 Q4 '22: -1063.00 Q1 '23: -1264.65 Q2 '23: -1404.00 Q3 '23: -1431.17 Q4 '23: -113.58 Q1 '24: -50.72 Q2 '24: 75.94 Q3 '24: 99.94 Q4 '25: -5.73 Q1 '26: -5.46 Q2 '26: -4.37 Q1 '17 Q4 '17 Q3 '18 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.